Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2006

View Archived Issues

Progesterone may be of benefit in treating brain trauma

PF-670462: new potent CKIe inhibitor evokes phase delays

RAMP-2 study of ultrasound contrast agent AI-700 completes enrollment

Preclinical characteristics of HCV protease inhibitor ITMN-191 described

Emergent and sanofi pasteur sign license agreement for novel meningitis B vaccine

Milestone in phase II study of Xanafide for secondary AML

Data from trial of eszopiclone in insomniac patients with depression further analyzed

Nastech enters into supply agreement with P&G for PTH (1-34) nasal spray

MTD defined for YM-155 in phase I trial

Continuous infusion of cilengitide associated with predictable pharmacokinetics

Results reported at ASCO for GTI-2040 in AML and HRPC

Second-generation fusion protein from Active Biotech shows activity in NSCLC and RCC

Denibulin shows promising activity and tolerability profile in advanced cancer patients

Preliminary results of phase I study of E-7820 discussed at major cancer meeting

Novel antiinfective agents patented

Recent patents report new therapeutic agents for metabolic disorders

Novel therapeutic options for cardiovascular diseases disclosed in recent patents

Preclinical results suggest NSD-503's potential utility in COPD

Enrollment opens in phase II study of AL-208 for CABG-associated MCI

Novartis to acquire NeuTec Pharma

Disappointing phase II results for oral levosimendan in severe chronic heart failure

Tanabe Seiyaku and Maruho conclude agreement for topical PDE4 inhibitor

Orphan drug designation for CellCept for pemphigus vulgaris

Phase I study for INCB-13739 for type 2 diabetes

Sirtris completes dosing in phase I study of SRT-501

Nereus studies NPI-2358 for solid tumors in phase I study

Serotonin 5-HT6 antagonist PRX-07034 begins phase I study

Phase II results for AMG-0001

Gardasil approved by FDA

Priority review for Zolinza NDA for advanced CTCL

Cialis Once-A-Day submitted for European review

Targeting bacterial fatty-acid biosynthesis with platensimycin effective against resistant bacteria

Phase I/II trials investigate safety, efficacy of [131I]-metuximab injection in liver cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...